Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17141883 | 0.87 | BACE1 (0.44) | HSD17B10BACE1KDM4ETSHRHPGD | |
| SCHEMBL5790165 | 0.82 | HSD17B10 (0.57) | HSD17B10BACE1KDM4ETSHRHPGD | |
| SCHEMBL31519324 | 0.81 | ABCB1 (0.52) | MAPTABCB1MEN1KMT2AABCG2 | |
| SCHEMBL30464743 | 0.80 | HSD17B10 (0.71) | HSD17B10BACE1KDM4ETSHRHPGD | |
| SCHEMBL4571036 | 0.80 | HSD17B10 (0.71) | HSD17B10BACE1KDM4ETSHRHPGD | |
| SCHEMBL893345 | 0.80 | HSD17B10 (0.60) | HSD17B10BACE1KDM4ETSHRHPGD | |
| Hydrochloric Acid SCHEMBL5598108 | 0.80 | HSD17B10 (0.55) | HSD17B10BACE1KDM4ETSHRHPGD | |
| SCHEMBL1520714 | 0.80 | HSD17B10 (0.55) | HSD17B10BACE1KDM4ETSHRHPGD | |
| SCHEMBL1520990 | 0.79 | IDO1 (0.50) | HSD17B10BACE1KDM4ETSHRHPGD | |
| SCHEMBL17813492 | 0.79 | HDAC8 (0.46) | HSD17B10BACE1KDM4ETSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2022-12-29 | — | — | US | disclosed |
| CN-110003172-B | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | 同步制药公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3939971-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3939971-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210171495-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2021-06-10 | — | — | US | disclosed |
| US-20210171495-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2021-06-10 | — | — | US | disclosed |
| EP-3129366-B1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYNCHRONICITY PHARMA INC (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3129366-B1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYNCHRONICITY PHARMA INC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10005759-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005759-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| CN-106458891-A | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | 复位治疗公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-3129366-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Reset Therapeutics, Inc. (US) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015157182-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015157182-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150284362-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150284362-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2015-10-08 | — | — | US | disclosed |
| CN-102146007-B | Method for preparing secondary amine and tertiary amine | DALIAN CHEMICAL PHYSICS INST | 2013-10-23 | — | — | CN | disclosed |
| CN-102146007-A | Method for preparing secondary amine and tertiary amine | DALIAN CHEMICAL PHYSICS INST | 2011-08-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284362-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | HSD17B10 1044/4885BACE1 1557/4885KDM4E 1254/4885 |
| US-20210171495-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | HSD17B10 1044/4885BACE1 1557/4885KDM4E 1254/4885 |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | HSD17B10 1044/4885BACE1 1557/4885KDM4E 1254/4885 |
| US-10005759-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | CRY1, CRY2, HCCS | HSD17B10 1044/4885BACE1 1557/4885KDM4E 1254/4885 |
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | HSD17B10 1044/4885BACE1 1557/4885KDM4E 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.